Kymera Therapeutics (KYMR) reported on its Q3 FY2025 performance ending September 30, 2025, highlighted by significant R&D acceleration against declining revenue, necessitating continued reliance on substantial equity financing.
Financial Performance & Costs The company sustained and widened its net losses year-over-year. Nine-month Net Loss increased to \((\\)224.4M)\( (from \)($153.1M)\( in 2024), pushing Diluted Loss Per Share to \)($2.71)\(. Collaboration Revenue declined to \)$36.34M\( YTD. Total Operating Expenses surged, driven by a substantial increase in R&D spending to \)$232.7M$ YTD,
...